nach oben

Erschienen in:

01.07.2006 | Current Opinion

Are there Differential Symptom Profiles that Improve in Response to Different Pharmacological Treatments of Premenstrual Syndrome/Premenstrual Dysphoric Disorder?

verfasst von: Dr Uriel Halbreich, PM Shaughn O’Brien, Elias Eriksson, Torbjörn Bäckström, Kimberly A. Yonkers, Ellen W. Freeman

Erschienen in: CNS Drugs | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

Current evidence suggests that the accepted treatments for premenstrual syndrome (PMS)/premenstrual dysphoric disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (<60%), such that, irrespective of treatment modality, there remain a significant number of women who are unresponsive to current conventional pharmacological therapy.

The available data on response rates of specific types of premenstrual symptoms to, or symptom profiles that are most amenable to, each treatment modality are limited and not well defined because most studies were not designed to assess specific symptom profiles. Those studies that have attempted to evaluate which symptom profiles respond to specific therapies have revealed variations within the individual modalities, as well as between the different modalities. It appears that suppression of ovulation ameliorates a broad range of behavioural as well as physical premenstrual symptoms. SSRIs are most effective for irritability and anxiety symptoms, with lesser efficacy for ‘atypical’ premenstrual symptoms. GABAergic compounds are most efficacious for anxiety and anxious/depressive symptoms, while dopamine agonists, particularly bromocriptine, are perhaps most efficacious for mastalgia.

Overall treatment response rates may improve if treatments are targeted at well-defined subgroups of patients. Re-analysis of available datasets from randomised clinical trials may shed more light on the notion that targeting women with specific premenstrual symptom profiles for specific treatment modalities would improve response rates beyond the current ceiling of approximately 60%. Such information would also improve understanding of the putative pathophysiological mechanisms underlying PMS and PMDD, and may point to a more specific diagnosis of these conditions.

The use of trade names is for product identification purposes only and does not imply endorsement.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington,DC. American Psychiatric Association, 1994: 714–8

Halbreich U, Borenstein J, Pearlstein T, et al. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28 Suppl. 3: 1–23

Perkonigg A, Yonkers KA, Pfister H, et al. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 2004; 65(10): 1314–22PubMedCrossRef

Wittchen HU, Becker E, Lieb R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002; 32(1): 119–32PubMedCrossRef

Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999; 8(2): 122–8PubMedCrossRef

Freeman EW. Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology 2003; 28 Suppl. 3: 25–37PubMedCrossRef

Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder: clinical procedures and research perspectives. Gynecol Endocrinol 2004; 19(6): 320–34PubMedCrossRef

Halbreich U, Endicott J, Schacht S, et al. The diversity of premenstrual changes as reflected in the Premenstrual Assessment Form. Acta Psychiatr Scand 1982; 65(1): 46–65PubMedCrossRef

American College of Obstetricians and Gynecologists. Premenstrual syndrome. Washington,DC: National Guideline Clearinghouse, 2000

10.

World Health Organization. International classification of diseases. 10th rev. Geneva: World Health Organization, 1996

11.

Hammarbäck S, Ekholm UB, Bäckström T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol (Copenh) 1991; 125(2): 132–7

12.

Hammarbäck S, Bäckström T, Holst J, et al. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy. Acta Obstet Gynecol Scand 1985; 64(5): 393–7PubMedCrossRef

13.

Magos AL, Brewster E, Singh R, et al. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 1986; 93(12): 1290–6PubMedCrossRef

14.

Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990; 162(1): 105–9PubMed

15.

Casson P, Hahn PM, Van Vugt DA, et al. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990; 162(1): 99–105PubMed

16.

Hammarbäck S, Bäckström T. Induced anovulation as treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 1988; 67(2): 159–66PubMedCrossRef

17.

Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991; 72(2): 252A-FCrossRef

18.

Hussain SY, Massil JH, Matta WH, et al. Buserelin in premenstrual syndrome. Gynecol Endocrinol 1992; 6(1): 57–64PubMedCrossRef

19.

Brown CS, Ling FW, Andersen RN, et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994; 84(5): 779–86PubMed

20.

West CP, Hillier H. Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum Reprod 1994; 9(6): 1058–63PubMed

21.

Freeman EW, Sondheimer SJ, Rickeis K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 1997; 33(2): 303–9PubMed

22.

Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998; 338(4): 209–16PubMedCrossRef

23.

Leather AT, Studd JW, Watson NR, et al. The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy: a placebo-controlled study. Gynecol Endocrinol 1999; 13(1): 48–55PubMedCrossRef

24.

Sundstrom I, Nyberg S, Bixo M, et al. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 1999; 78(10): 891–9PubMedCrossRef

25.

Di Carlo C, Palomba S, Tommaselli GA, et al. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 2001; 75(2): 380–4PubMedCrossRef

26.

Gilmore DH, Hawthorn RJ, Hart DM. Danazol for premenstrual syndrome: a preliminary report of a placebo-controlled double-blind study. J Int Med Res 1985; 13: 129–30PubMed

27.

Watts JF, Butt WR, Logan Edwards R. A clinical trial using danazol for the treatment of premenstrual tension. Br J Obstet Gynaecol 1987; 94(1): 30–4PubMedCrossRef

28.

Watts JF, Edwards RL, Butt WR. Treatment of premenstrual syndrome using danazol: preliminary report of a placebo-controlled, double-blind, dose ranging study. J Int Med Res 1985; 13: 127–8PubMed

29.

Gilmore DH, Hawthorn RJS, Hart DM. Treatment of the premenstrual syndrome: a double-blind placebo-controlled crossover study using danazol. J Obstet Gynaecol 1989; 9: 318–22CrossRef

30.

Deeny M, Hawthorn R, McKay Hart D. Low dose danazol in the treatment of the premenstrual syndrome. Postgrad Med J 1991; 67(787): 450–4PubMedCrossRef

31.

Fentiman IS, Caleffi M, Brame K, et al. Double-blind controlled trial of tamoxifen therapy for mastalgia. Lancet 1986; I(8476): 287–8CrossRef

32.

Magos AL, Brincat M, Studd JW. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. BMJ (Clin Res Ed) 1986; 292(6536): 1629–33CrossRef

33.

Messinis IE, Lolis D. Treatment of premenstrual mastalgia with tamoxifen. Acta Obstet Gynecol Scand 1988; 67(4): 307–9PubMed

34.

Watson NR, Studd JW, Savvas M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989; II(8665): 730–2CrossRef

35.

Dhar V, Murphy BE. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology 1990; 15(5–6): 489–93PubMedCrossRef

36.

Kontostolis E, Stefanidis K, Navrozoglou I, et al. Comparison of tamoxifen with danazol for treatment of cyclical mastalgia. Gynecol Endocrinol 1997; 11(6): 393–7PubMedCrossRef

37.

Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992; 36(3): 257–66PubMedCrossRef

38.

Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10(6): 561–9PubMedCrossRef

39.

Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-conatining oral contraceptive formulation. Contraception 2005 Dec; 72(6): 414–21PubMedCrossRef

40.

Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106(3): 492–501PubMedCrossRef

41.

Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003;28Suppl. 3: 39–53PubMedCrossRef

42.

Johnson SR. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners. Obstet Gynecol 2004; 104(4): 845–59PubMedCrossRef

43.

Studd J, Leather AT. The need for add-back with gonadotrophin-releasing hormone agonist therapy. Br J Obstet Gynaecol 1996; 103 Suppl. 14: 1–4PubMed

44.

Wyatt KM, Dimmock PW, Ismail KM, et al. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG 2004; 111(6): 585–93PubMedCrossRef

45.

Halbreich U. Algorithm for treatment of premenstrual syndromes (PMS): experts’ recommendations and limitations. Gynecol Endocrinol 2005; 20(1): 48–56PubMedCrossRef

46.

Magill PJ. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome, progesterone Study Group. Br J Gen Pract 1995; 45(400): 589–93PubMed

47.

Maddox PR, Harrison BJ, Horobin JM, et al. A randomised controlled trial of medroxyprogesterone acetate in mastalgia. Ann R Coll Surg Engl 1990; 72(2): 71–6PubMed

48.

Vanselow W, Dennerstein L, Greenwood KM, et al. Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration. J Psychosom Obstet Gynaecol 1996; 17(1): 29–38PubMedCrossRef

49.

Oinonen KA, Mazmanian D. To what extent do oral contraceptives influence mood and affect? J Affect Disord 2002; 70(3): 229–40PubMedCrossRef

50.

Kahn LS, Halbreich U. Oral contraceptives and mood. Expert Opin Pharmacother 2001; 2(9): 1367–82PubMedCrossRef

51.

Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54(4): 243–51PubMedCrossRef

52.

Eriksson E, Sundblad C, Lisjo P, et al. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology 1992; 17(2–3): 195–204PubMedCrossRef

53.

Wang M, Hammarbäck S, Lindhe BA, et al. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995; 74(10): 803–8PubMedCrossRef

54.

Rapkin AJ. The role of serotonin in premenstrual syndrome. Clin Obstet Gynecol 1992; 35(3): 629–36PubMedCrossRef

55.

Kouri EM, Halbreich U. State and trait serotonergic abnormalities in women with dysphoric premenstrual syndromes. Psychopharmacol Bull 1997; 33(4): 767–70PubMed

56.

Veeninga AT, Westenberg HG, Weusten JT. Fluvoxamine in the treatment of menstrually related mood disorders. Psychopharmacology (Berl) 1990; 102(3): 414–6CrossRef

57.

Eriksson E, Hedberg MA, Andersch B, et al. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995; 12(2): 167–76PubMedCrossRef

58.

Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/ Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995; 332(23): 1529–34

59.

Su TP, Schmidt PJ, Danaceau MA, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 1997; 16(5): 346–56PubMedCrossRef

60.

Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997; 278(12): 983–8PubMedCrossRef

61.

Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998; 18(5): 390–8PubMedCrossRef

62.

Freeman EW, Rickels K, Sondheimer SJ, et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999; 56(10): 932–9PubMedCrossRef

63.

Steiner M, Romano SJ, Babcock S, et al. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. BJOG 2001; 108(5): 462–8PubMed

64.

Cohen LS, Miner C, Brown EW, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002; 100(3): 435–44PubMedCrossRef

65.

Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002; 100(6): 1219–29PubMedCrossRef

66.

Miner C, Brown E, McCray S, et al. Weekly luteal-phase dosing with enteric-coated fluoxetine 90mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002; 24(3): 417–33PubMedCrossRef

67.

Freeman EW, Rickels K, Sondheimer SJ, et al. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder.Am J Psychiatry 2004; 161(2): 343–51PubMedCrossRef

68.

Steiner M, Hirschberg AL, Bergeron R, et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005; 193(2): 352–60PubMedCrossRef

69.

Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome. Lancet 1989; I(8641): 777CrossRef

70.

Sundblad C, Modigh K, Andersch B, et al. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 1992; 85(1): 39–47PubMedCrossRef

71.

Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 1993; 9(2): 133–45PubMed

72.

Eriksson E, Andersch B, Ho HP, et al. Diagnosis and treatment of premenstrual dysphoria. J Clin Psychiatry 2002; 63 Suppl. 7: 16–23PubMed

73.

Pearlstein TB, Stone AB, Lund SA, et al. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997; 17(4): 261–6PubMedCrossRef

74.

Taghavi E, Menkes DB, Howard RC, et al. Premenstrual syndrome: a double-blind controlled trial of desipramine and methylscopolamine. Int Clin Psychopharmacol 1995; 10(2): 119–22PubMedCrossRef

75.

Freeman EW, Rickels K, Sondheimer SJ, et al. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995; 274(1): 51–7PubMedCrossRef

76.

Yonkers KA, Halbreich U, Freeman E, et al. Sertraline in the treatment of premenstrual dysphoric disorder. Psychopharmacol Bull 1996; 32(1): 41–6PubMed

77.

Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000; 356(9236): 1131–6PubMedCrossRef

78.

Freeman EW, Sondheimer SJ, Rickels K, et al. Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study. J Clin Psychiatry 1993; 54(5): 192–5PubMed

79.

Halbreich U, Rojansky N, Palter S. Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes. Fertil Steril 1991; 56(6): 1066–9PubMed

80.

Freeman E, Rickels K, Sondheimer SJ, et al. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome.JAMA 1990; 264(3): 349–53PubMedCrossRef

81.

Wyatt K, Dimmock P, Jones P, et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001; 323(7316): 776–80PubMedCrossRef

82.

Dennerstein L, Spencer-Gardner C, Gotts G, et al. Progesterone and the premenstrual syndrome: a double blind crossover trial. BMJ (Clin Res Ed) 1985; 290(6482): 1617–21CrossRef

83.

West CP. Inhibition of ovulation with oral progestins: effectiveness in premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol 1990; 34(1–2): 119–28PubMedCrossRef

84.

Dennerstein L, Morse C, Gotts G, et al. Treatment of premenstrual syndrome: a double-blind trial of dydrogesterone. J Affect Disord 1986; 11(3): 199–205PubMedCrossRef

85.

Williams JGC, Martin AJ, Hulkenberg-Tromp A. Premenstrual syndrome in four European countries: part 2. A double-blind controlled study of dydrogesterone. Br J Sex Med 1983; 10: 8–18

86.

Sanders SA, Graham CA, Bass JL, et al. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 2001; 64(1): 51–8PubMedCrossRef

87.

Walker A, Bancroft J. Relationship between premenstrual symptoms and oral contraceptive use: a controlled study. Psychosom Med 1990; 52(1): 86–96PubMed

88.

Cohen LS, Soares CN, Lyster A, et al. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 2004; 24(5): 540–3PubMedCrossRef

89.

Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997; 58(9): 399–402PubMedCrossRef

90.

Landen M, Eriksson O, Sundblad C, et al. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl) 2001; 155(3): 292–8CrossRef

91.

Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98 (5 Pt 1): 737–44PubMedCrossRef

92.

Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam: a controlled study. Arch Gen Psychiatry 1990; 47(3): 270–5PubMedCrossRef

93.

Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1993; 50(6): 467–73PubMedCrossRef

94.

Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol 1994; 84(3): 379–85PubMed

95.

Evans SM, Haney M, Levin FR, et al. Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam. Neuropsychopharmacology 1998; 19(6): 499–516PubMedCrossRef

96.

Evans SM, Foltin RW, Fischman MW. Food ‘cravings’ and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder. Appetite 1999; 32(3): 331–49PubMedCrossRef

97.

Halbreich U, Ben-David M, Assael M, et al. Serum-prolatic in women with premenstrual syndrome. Lancet 1976; II(7987): 654–6CrossRef

98.

Benedek-Jaszmann LJ, Hearn-Sturtevant MD. Premenstrual tension and functional infertility: aetiology and treatment. Lancet 1976; I(7969): 1095–8CrossRef

99.

Graham JJ, Harding PE, Wise PH, et al. Prolactin suppression in the treatment of premenstrual syndrome. Med J Aust 1978; 2(3 Suppl.): 18–20PubMed

100.

Eisner CW, Buster JE, Schindler RA, et al. Bromocriptine in the treatment of premenstrual tension syndrome. Obstet Gynecol 1980; 56(6): 723–6

101.

Ylostalo P, Kauppila A, Puolakka J, et al. Bromocriptine and norethisterone in the treatment of premenstrual syndrome. Obstet Gynecol 1981; 58: 292–8

102.

Meden-Vrtovec H, Vujic D. Bromocriptine (Bromergon, Lek) in the management of premenstrual syndrome. Clin Exp Obstet Gynecol 1992; 19(4): 242–8PubMed

103.

Ghose K, Coppen A. Bromocriptine and premenstrual syndrome: controlled study. BMJ 1977; 1(6054): 147–8PubMedCrossRef

104.

Andersch B, Hahn L. Bromocriptine and premenstrual tension: a clinical and hormonal study. Pharmatherapeutica 1982; 3(2): 107–13PubMed

105.

Andersen AN, Larsen JF, Steenstrup OR, et al. Effect of bromocriptine on the premenstrual syndrome: a double-blind clinical trial. Br J Obstet Gynaecol 1977; 84(5): 370–4PubMedCrossRef

106.

Kullander S, Svanberg L. Bromocriptine treatment of the premenstrual syndrome. Acta Obstet Gynecol Scand 1979; 58(4): 375–8PubMedCrossRef

107.

Mansel RE, Dogliotti L. European multicentre trial of bromocriptine in cyclical mastalgia. Lancet 1990; 335(8683): 190–3PubMedCrossRef

108.

Kaleli S, Aydin Y, Erel CT, et al. Symptomatic treatment of premenstrual mastalgia in premenopausal women with lisuride maleate: a double-blind placebo-controlled randomized study. Fertil Steril 2001; 75(4): 718–23PubMedCrossRef

109.

O’Brien PM, Craven D, Selby C, et al. Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynaecol 1979; 86(2): 142–7PubMedCrossRef

110.

Vellacott ID, Shroff NE, Pearce MY, et al. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin 1987; 10(7): 450–6PubMedCrossRef

111.

Burnet RB, Radden HS, Easterbrook EG, et al. Premenstrual syndrome and spironolactone. Aust N Z J Obstet Gynaecol 1991; 31(4): 366–8PubMedCrossRef

112.

Hellberg D, Claesson B, Nilsson S. Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate. Int J Gynaecol Obstet 1991; 34(3): 243–8PubMedCrossRef

113.

Aslaksen K, Falk V. Spironolactone in the treatment of premenstrual tension: a double-blind study of spironolactone versus bendroflumethiaxide and placebo. Curr Ther Res 1991; 49: 120–30

Titel: Are there Differential Symptom Profiles that Improve in Response to Different Pharmacological Treatments of Premenstrual Syndrome/Premenstrual Dysphoric Disorder?
verfasst von: Dr Uriel Halbreich
PM Shaughn O’Brien
Elias Eriksson
Torbjörn Bäckström
Kimberly A. Yonkers
Ellen W. Freeman
Publikationsdatum: 01.07.2006
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 7/2006
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200620070-00001

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2006

Economics of Atypical Antipsychotics in Bipolar Disorder

Sleep Disturbances in Patients with Post-Traumatic Stress Disorder

Retigabine in Partial Seizures

Pharmacological Aspects of the Treatment of Conduct Disorder in Children and Adolescents